Studies have reported numerous advanced therapies for treating psoriatic arthritis (PsA), Crohn’s disease (CD), ulcerative colitis (UC), and uveitis. Now, a recent review published in The Journal of Rheumatology has highlighted that advanced therapies are not equally beneficial for PsA and related conditions.
Jadon and co-researchers have reviewed 32 randomized controlled trials in inflammatory bowel disease and uveitis for updating the recommendations for PsA patients. The researchers advocated the need for advanced therapeutic algorithms for the personalized care of PsA patients and the adoption of multispecialty approach for the holistic management of such patients.
Current recommendations have reported tumor necrosis factor inhibitors to be safe and more effective than etanercept for treating CD, UC, and uveitis. Phase II and III trials have provided promising results on the safety and efficacy of Janus kinase inhibitors and interleukin 12/23 inhibitors in CD and UC. Experts have recommended the cautious use of interleukin-17 inhibitors in PsA patients with elevated risk of inflammatory bowel disease.
Experts emphasized the need to consider inflammatory bowel disease and uveitis in patients with PsA and related conditions. Moreover, the safety profiles of different biologics and small-molecule therapies must be elaborated in the future for treating these PsA patients.
Reference
- Jadon DR, Corp N, Windt DA van der, Coates LC, Soriano ER, Kavanaugh A, et al. Management of Concomitant Inflammatory Bowel Disease or Uveitis in Patients with Psoriatic Arthritis: An Updated Review Informing the 2021 GRAPPA Treatment Recommendations. The Journal of Rheumatology. 2023 Mar 1;50(3):438–50.